Group One Trading, L.P. Janux Therapeutics, Inc. Transaction History
Group One Trading, L.P.
- $3.01 Billion
- Q2 2024
A detailed history of Group One Trading, L.P. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 381 shares of JANX stock, worth $18,409. This represents 0.0% of its overall portfolio holdings.
Number of Shares
381Holding current value
$18,409% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
161Shares Held
36.8MCall Options Held
72.2KPut Options Held
103K-
Ra Capital Management, L.P. Boston, MA9.17MShares$443 Million5.79% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.98MShares$144 Million3.01% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$113 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.33MShares$112 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X01.8MShares$87.1 Million0.04% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.01B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...